23 results on '"Chulanov, Vladimir"'
Search Results
2. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update
3. Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide
4. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
5. Transient and tunable CRISPRa regulation of APOBEC/AID genes for targeting hepatitis B virus
6. Technological aspects of manufacturing and analytical control of biological nanoparticles
7. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
8. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
9. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
10. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
11. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
12. WED-158 - Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D
13. WED-395 Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta
14. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy
15. TOP-400 Impact of bulevirtide given with or without nucleos (t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection
16. LBP-029 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301
17. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204
18. Sa1626 HIGH RATES OF ADHERENCE TO BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS DELTA THROUGH 96 WEEKS: RESULTS FROM AN INTERIM ANALYSIS OF THE PHASE 3 STUDY MYR301
19. Sa1618 EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
20. P-6 SOFOSBUVIR CONTAINING REGIMENS ARE SAFE AND EFFECTIVE IN ADOLESCENTS WITH CHRONIC HEPATITIS C INFECTION
21. OS-068 - Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
22. Mo1537 EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
23. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.